{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:33:19Z","timestamp":1771471999756,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T00:00:00Z","timestamp":1467763200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Vessels"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00380-016-0872-4","type":"journal-article","created":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T09:03:44Z","timestamp":1467795824000},"page":"287-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1014-7447","authenticated-orcid":false,"given":"Akihisa","family":"Hanatani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryouko","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Sugioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Yoshiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,6]]},"reference":[{"issue":"1","key":"872_CR1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1161\/CIRCHEARTFAILURE.108.821785","volume":"2","author":"GM Felker","year":"2009","unstructured":"Felker GM, O\u2019Connor CM, Braunwald E, Heart Failure Clinical Research Network Investigators (2009) Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2(1):56\u201362","journal-title":"Circ Heart Fail"},{"key":"872_CR2","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.amjcard.2005.12.072","volume":"97","author":"S Eshaghian","year":"2006","unstructured":"Eshaghian S, Horwich TB, Fonarow GC (2006) Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97:1759\u20131764","journal-title":"Am J Cardiol"},{"key":"872_CR3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1253\/circj.CJ-13-0187","volume":"77","author":"N Sato","year":"2013","unstructured":"Sato N, Kajimoto K, Keida T, Mizuno M, Minami Y, Yumino D, Asai K, Murai K, Muanakata R, Aokage T, Sakata Y, Mizuno K, Takano T, ATEND Investigators (2013) Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 77:944\u2013951","journal-title":"Circ J"},{"issue":"Suppl 1","key":"872_CR4","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/s10557-011-6349-x","volume":"25","author":"T Inomata","year":"2011","unstructured":"Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A (2011) Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 25(Suppl 1):S57\u2013S65","journal-title":"Cardiovasc Drugs Ther"},{"issue":"Suppl 1","key":"872_CR5","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","volume":"25","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Hori M, Izumi T, Fukunami M, Tolvaptan Investigators (2011) Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 25(Suppl 1):S33\u2013S45","journal-title":"Cardiovasc Drugs Ther"},{"key":"872_CR6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T (1998) OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287:860\u2013867","journal-title":"J Pharmacol Exp Ther"},{"key":"872_CR7","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","volume":"290","author":"LC Costello-Boerrigter","year":"2006","unstructured":"Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr (2006) Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human. Am J Physiol Renal Physiol 290:F273\u2013F278","journal-title":"Am J Physiol Renal Physiol"},{"key":"872_CR8","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","volume":"107","author":"M Gheorghiade","year":"2003","unstructured":"Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C, Investigators Tolvaptan (2003) Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107:2690\u20132696","journal-title":"Circulation"},{"key":"872_CR9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jjcc.2012.08.020","volume":"61","author":"Y Matsue","year":"2013","unstructured":"Matsue Y, Suzuki M, Seya M, Iwatsuka R, Mizukami A, Nagahori W, Ohno M, Matsumura A, Hashimoto Y (2013) Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 61:169\u2013174","journal-title":"J Cardiol"},{"key":"872_CR10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1536\/ihj.54.377","volume":"54","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Hatano M, Yao A, Komuro I (2013) Tolvaptan can improve clinical course in responders validation analysis for the definition of responsiveness by urine volume. Int Heart J 54:377\u2013381","journal-title":"Int Heart J"},{"key":"872_CR11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ahj.2004.08.005","volume":"149","author":"KF Adams Jr","year":"2005","unstructured":"Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP, ADHERE Scientific Advisory Committee Investigators (2005) Characteristics, outcomes of patients hospitalized for heart failure in the United States: rationale, design, preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149:209\u2013216","journal-title":"Am Heart J"},{"key":"872_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","volume":"103","author":"GS Francis","year":"1985","unstructured":"Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN (1985) Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart-failure: activation of the neurohumoral axis. Ann Intern Med 103:1\u20136","journal-title":"Ann Intern Med"},{"key":"872_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-015-0688-7","author":"Y Nakada","year":"2015","unstructured":"Nakada Y, Takahama H, Kanzaki H, Sugano Y, Hasegawa T, Ohara T, Amaki M, Funada A, Yoshida A, Yasuda S, Ogawa H, Anzai T (2015) The predictability of renin\u2013angiotensin\u2013aldosterone system factors for clinical outcome in patients with acute decompensated heart failure. Heart Vessels. doi: 10.1007\/s00380-015-0688-7","journal-title":"Heart Vessels"},{"key":"872_CR14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0009-9236(97)90067-9","volume":"62","author":"G Cotter","year":"1997","unstructured":"Cotter G, Weissgarten J, Metzkor E, Moshkovitz Y, Litinski I, Tavori U, Perry C, Zaidenstein R, Golik A (1997) Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther 62:187\u2013193","journal-title":"Clin Pharmacol Ther"},{"key":"872_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-016-0817-y","author":"Y Matsue","year":"2016","unstructured":"Matsue Y, Shiraishi A, Kagiyama N, Yoshida K, Kume T, Okura H, Suzuki M, Matsumura A, Yoshida K, Hashimoto Y (2016) Renal function on admission modifies prognostic impact of diuretics in acute heart failure: a propensity score matched and interaction analysis. Heart Vessels. doi: 10.1007\/s00380-016-0817-y","journal-title":"Heart Vessels"},{"key":"872_CR16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jacc.2003.07.031","volume":"43","author":"DE Forman","year":"2004","unstructured":"Forman DE, Butler J, Wang Y, Abraham WT, O\u2019Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM (2004) Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43:61\u201367","journal-title":"J Am Coll Cardiol"},{"key":"872_CR17","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/eurheartj\/ehi859","volume":"27","author":"MR Cowie","year":"2006","unstructured":"Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B, POSH Investigators (2006) Prevalence, impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 27:1216\u20131222","journal-title":"Eur Heart J"},{"key":"872_CR18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejheart.2008.01.011","volume":"10","author":"M Metra","year":"2008","unstructured":"Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, Fontanella B, Lombardi C, Milani P, Verzura G, Cotter G, Dittrich H, Massie BM, Dei Cas L (2008) Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail 10:188\u2013195","journal-title":"Eur J Heart Fail"},{"key":"872_CR19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ahj.2010.05.032","volume":"160","author":"HM Abdel-Qadir","year":"2010","unstructured":"Abdel-Qadir HM, Tu JV, Yun L, Austin PC, Newton GE, Lee DS (2010) Diuretic dose, long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J 160:264\u2013271","journal-title":"Am Heart J"},{"key":"872_CR20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","volume":"35","author":"K Damman","year":"2014","unstructured":"Damman K, Valente MA, Voors AA, O\u2019Connor CM, van Veldhuisen DJ, Hillege HL (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35:455\u2013469","journal-title":"Eur Heart J"},{"key":"872_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-014-0572-x","author":"Y Takaya","year":"2016","unstructured":"Takaya Y, Yoshihara F, Yokoyama H, Kanzaki H, Kitakaze M, Goto Y, Anzai T, Yasuda S, Ogawa H, Kawano Y (2016) Impact of onset time of acute kidney injury on outcomes in patients with acute decompensated heart failure. Heart Vessels. doi: 10.1007\/s00380-014-0572-x","journal-title":"Heart Vessels"},{"key":"872_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-015-0780-z","author":"R Matsukawa","year":"2015","unstructured":"Matsukawa R, Kubota T, Okabe M, Yamamoto Y (2015) Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure. Heart Vessels. doi: 10.1007\/s00380-015-0780-z","journal-title":"Heart Vessels"},{"key":"872_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-015-0775-9","author":"Y Uemura","year":"2015","unstructured":"Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, Mitsuda T, Miura A, Imai R, Iwamiya S, Ozaki Y, Kato T, Miura T, Watarai M, Murohara T (2015) Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease. Heart Vessels. doi: 10.1007\/s00380-015-0775-9","journal-title":"Heart Vessels"},{"key":"872_CR24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/hrt.57.1.17","volume":"57","author":"J Bayliss","year":"1987","unstructured":"Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P (1987) Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 57:17\u201322","journal-title":"Br Heart J"},{"issue":"Suppl 1","key":"872_CR25","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1007\/s10557-011-6350-4","volume":"25","author":"T Onogawa","year":"2011","unstructured":"Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y (2011) Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther 25(Suppl 1):S67\u2013S76","journal-title":"Cardiovasc Drugs Ther"},{"key":"872_CR26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jjcc.2015.09.020","volume":"67","author":"K Kimura","year":"2016","unstructured":"Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, Izawa A, Ikeda U (2016) Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol 67:399\u2013405","journal-title":"J Cardiol"},{"key":"872_CR27","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1067\/mhj.2000.110933","volume":"140","author":"C Lucas","year":"2000","unstructured":"Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW (2000) Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 140:840\u2013847","journal-title":"Am Heart J"},{"key":"872_CR28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJM199808063390607","volume":"339","author":"DC Brater","year":"1998","unstructured":"Brater DC (1998) Diuretic therapy. N Engl J Med 339:387\u2013395","journal-title":"N Engl J Med"},{"key":"872_CR29","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM199908193410806","volume":"341","author":"RW Schrier","year":"1999","unstructured":"Schrier RW, Abraham WT (1999) Hormones and hemodynamics in heart failure. N Engl J Med 341:577\u2013585","journal-title":"N Engl J Med"},{"key":"872_CR30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCHEARTFAILURE.111.963413","volume":"5","author":"M Metra","year":"2012","unstructured":"Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, Piovanelli B, Carubelli V, Bugatti S, Lombardi C, Cotter G, Dei Cas L (2012) Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail 5:54\u201362","journal-title":"Circ Heart Fail"},{"key":"872_CR31","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 297:1319\u20131331","journal-title":"JAMA"}],"container-title":["Heart and Vessels"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-016-0872-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00380-016-0872-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-016-0872-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00380-016-0872-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:03:22Z","timestamp":1748995402000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00380-016-0872-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,6]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1007\/s00380-016-0872-4","relation":{},"ISSN":["0910-8327","1615-2573"],"issn-type":[{"value":"0910-8327","type":"print"},{"value":"1615-2573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,6]]}}}